Real-World Evidence Study of Patients with <i>KRAS</i>-Mutated NSCLC in Finland
While <i>KRAS</i> is the most frequently mutated oncogene in non-small cell lung cancer (NSCLC), <i>KRAS</i>-mutant tumors have long been considered difficult to treat and thus, an unmet need still remains. Partly due to the lack of targeted treatments, comprehensive real-wor...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-05-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/5/205 |